stella
beta
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk — Stella
Home
/
HCC
/
View on ClinicalTrials.gov
Recruiting
Back to HCC trials
Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations
(1 site)
China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan